Since 2016, the FDA has approved three disease-modifying treatments for spinal muscular atrophy, with several ...

For millions of people, losing muscle isn't just about weakness; it's about losing independence. Whether caused by Duchenne ...

A Prescription Drug User Fee Act (PDUFA) target action date for apitegromab has been set for Sept. 22, 2025.

Researchers have discovered a potential therapeutic target in muscular disorders by identifying a previously unrecognized ...

Muscle atrophy is the loss of muscle mass. Low physical activity, nutritional deficiencies, genetic factors, and some medical conditions may contribute. Muscle atrophy due to inactivity can occur ...

For millions of people, losing muscle isn't just about weakness; it's about losing independence. Whether caused by Duchenne muscular dystrophy, aging or other degenerative conditions, muscle loss can ...

Muscular dystrophy is a group of inherited diseases (more than 30) that causes skeletal muscle weakness and wasting that worsens over time. The genes involved in muscular dystrophy normally code ...

Their technique opens the way for using implantation to treat unscarred muscle atrophied by aging. Age-related muscular atrophy in skeletal muscle can have a devastating impact on people's quality ...

Muscle wasting was detected in 39 (19.5% ... Future studies will be needed to establish clinical approaches to stop or reserve skeletal muscle loss. Pharmacological inhibition of myostatin ...